UniQure Net Income 2013-2022 | QURE
UniQure net income from 2013 to 2022. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
UniQure Annual Net Income
(Millions of US $) |
| 2021 |
$330 |
| 2020 |
$-125 |
| 2019 |
$-124 |
| 2018 |
$-83 |
| 2017 |
$-79 |
| 2016 |
$-73 |
| 2015 |
$-82 |
| 2014 |
$-50 |
| 2013 |
$-36 |
| 2012 |
$-19 |
UniQure Quarterly Net Income
(Millions of US $) |
| 2022-09-30 |
$-48 |
| 2022-06-30 |
$-39 |
| 2022-03-31 |
$-47 |
| 2021-12-31 |
$8 |
| 2021-09-30 |
$-37 |
| 2021-06-30 |
$399 |
| 2021-03-31 |
$-42 |
| 2020-12-31 |
$-1 |
| 2020-09-30 |
$-54 |
| 2020-06-30 |
$-43 |
| 2020-03-31 |
$-28 |
| 2019-12-31 |
$-41 |
| 2019-09-30 |
$-24 |
| 2019-06-30 |
$-31 |
| 2019-03-31 |
$-28 |
| 2018-12-31 |
$-22 |
| 2018-09-30 |
$-22 |
| 2018-06-30 |
$-21 |
| 2018-03-31 |
$-19 |
| 2017-12-31 |
$-27 |
| 2017-09-30 |
$-10 |
| 2017-06-30 |
$-21 |
| 2017-03-31 |
$-20 |
| 2016-12-31 |
$-15 |
| 2016-09-30 |
$-15 |
| 2016-06-30 |
$-21 |
| 2016-03-31 |
$-22 |
| 2015-12-31 |
$-19 |
| 2015-09-30 |
$-29 |
| 2015-06-30 |
$-21 |
| 2015-03-31 |
$-14 |
| 2014-12-31 |
$-0 |
| 2014-09-30 |
$-11 |
| 2014-06-30 |
$-12 |
| 2014-03-31 |
$-11 |
| 2013-12-31 |
|
| 2013-09-30 |
|
| 2012-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$1.001B |
$0.524B |
|
UNIQURE B.V. is involved in developing gene therapy for patients of genetic or acquired diseases. It offers Glybera for the treatment of lipoprotein lipase deficiency, an orphan metabolic disease. The company's product pipeline includes which are in clinical trials are additional adeno-associated virus consist of AMT-060, AMT-021, AMT-110 and AAV2/glial. UNIQURE B.V. is headquartered in Amsterdam, the Netherlands.
|
